Why the study?
Does the RRV-TV vaccine improve immunogenicity and prevent rotavirus diarrhea in infants?
Does the RRV-TV vaccine improve immunogenicity and prevent rotavirus diarrhea in infants?
The RRV-TV vaccine induced significant immune responses and provided partial protection against severe rotavirus diarrhea, though it failed to significantly protect against all rotavirus diarrhea episodes.
Answers are grounded in this paper and cite their sources.
Supports RRV-TV for reducing severe rotavirus diarrhea in infants; confirms immunogenicity but leaves open full protection against all episodes.
An oral rhesus-human rotavirus tetravalent (RRV-TV) vaccine (10(4) pfu of rhesus rotavirus [type G3] and of 3 human-rhesus reassortants [G1, G2, and G4]) was evaluated in a field trial in Lima, Peru. At 2, 3, and 4 months of age, infants received either a dose of RRV-TV, an initial dose of vaccine followed by a dose of placebo at 3 and 4 months, or a dose of placebo. Rotavirus-specific IgA responses were detected by ELISA in 75% of the three-dose vaccine group, 59% of the one-dose vaccine group (P = .05), and 24% of the placebo group (P < .001): 64%, 48%, and 12% of each group, respectively, had a neutralizing antibody response to at least 1 serotype. Both one and three doses of vaccine failed to induce a significant level of protection against rotavirus diarrhea; however, they did provide some protection (range, 35%-66%) against more severe rotavirus diarrhea, especially for episodes caused by type G1.
No takes yet. Share an insight, caveat, or question.
Lanata et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: